Ravulizumab Recruiting Phase 3 Trials for Neuromyelitis Optica Spectrum Disorder / Neuromyelitis Optica Treatment

IndicationsStatusPurposePhase
RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT04201262An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD